文献速递新发突发、热带与寄生虫病

坦桑尼亚成人中PfSPZ疫苗剂量增加与保护力下降相关

Increase of Dose Associated With Decrease in Protection Against Controlled Human Malaria Infection by PfSPZ Vaccine in Tanzanian Adults.
PubMed 文献 · Clin Infect Dis · 2020-01-01

在坦桑尼亚成人中开展双盲安慰剂对照试验,评估不同剂量PfSPZ疫苗对控制性人类疟疾感染(CHMI)的保护效果。结果显示,剂量从2.7×10^5增至9×10^5 PfSPZ时疫苗效力(VE)从20%升至100%,但增至1.8×10^6时VE降至33%。

要点

  • 坦桑尼亚成人中5剂2.7×10^5 PfSPZ疫苗的VE仅20%。
  • 增至9×10^5 PfSPZ、3剂方案VE达100%(5/5),但1.8×10^6剂量VE降至33%。
  • 高剂量组抗体和T细胞应答更高,但未转化为更高保护力。

核心结论

  • 在坦桑尼亚成人中,将PfSPZ疫苗剂量从2.7×10^5增至9×10^5 PfSPZ使VE从20%升至100%,但进一步增至1.8×10^6 PfSPZ则显著降低VE至33%。

研究设计与样本

  • 双盲、安慰剂对照试验,在坦桑尼亚成人中比较不同剂量PfSPZ疫苗(9×10^5或1.8×10^6 PfSPZ,3剂,间隔8周)对CHMI的保护效果,并设对照组。

主要发现

  • 对照组22例CHMI均经定量PCR检出寄生虫血症。
  • 1.8×10^6 PfSPZ组在7.5周时VE为33%(2/6)(P = .028)。
  • 两剂量组VE(100% vs 33%)差异显著(P = .022)。
  • 末次给药后37-40周重复CHMI,9×10^5组首次寄生虫血症时间显著长于对照(10.89 vs 7.80天)(P = .039)。

关键数值与推荐

  • 9×10^5 PfSPZ组VE 100%(5/5),1.8×10^6 PfSPZ组VE 33%(2/6),组间差异P = .022。
  • 重复CHMI中9×10^5组6/6、1.8×10^6组5/6出现寄生虫血症。

临床怎么用

  • 在疟疾高传播区成人中,PfSPZ疫苗的剂量-保护关系非单调,需谨慎选择剂量进行后续开发。

局限性

  • 样本量小(各组5-6例),结果需更大规模试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A vaccine would be an ideal tool for reducing malaria's impact. PfSPZ Vaccine (radiation attenuated, aseptic, purified, cryopreserved Plasmodium falciparum [Pf] sporozoites [SPZ]) has been well tolerated and safe in >1526 malaria-naive and experienced 6-month to 65-year-olds in the United States, Europe, and Africa. When vaccine efficacy (VE) of 5 doses of 2.7 × 105 PfSPZ of PfSPZ Vaccine was assessed in adults against controlled human malaria infection (CHMI) in the United States and Tanzania and intense field transmission of heterogeneous Pf in Mali, Tanzanians had the lowest VE (20%). METHODS: To increase VE in Tanzania, we increased PfSPZ/dose (9 × 105 or 1.8 × 106) and decreased numbers of doses to 3 at 8-week intervals in a double blind, placebo-controlled trial. RESULTS: All 22 CHMIs in controls resulted in parasitemia by quantitative polymerase chain reaction. For the 9 × 105 PfSPZ group, VE was 100% (5/5) at 3 or 11 weeks (P < .000l, Barnard test, 2-tailed). For 1.8 × 106 PfSPZ, VE was 33% (2/6) at 7.5 weeks (P = .028). VE of dosage groups (100% vs 33%) was significantly different (P = .022). Volunteers underwent repeat CHMI at 37-40 weeks after last dose. 6/6 and 5/6 volunteers developed parasitemia, but time to first parasitemia was significantly longer than controls in the 9 × 105 PfSPZ group (10.89 vs 7.80 days) (P = .039), indicating a significant reduction in parasites in the liver. Antibody and T-cell responses were higher in the 1.8 × 106 PfSPZ group. CONCLUSIONS: In Tanzania, increasing the dose from 2.7 × 105 to 9 × 105 PfSPZ increased VE from 20% to 100%, but increasing to 1.8 × 106 PfSPZ significantly reduced VE. CLINICAL TRIALS REGISTRATION: NCT02613520.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Jongo SA, Church LWP, Mtoro AT, et al. Increase of Dose Associated With Decrease in Protection Against Controlled Human Malaria Infection by PfSPZ Vaccine in Tanzanian Adults. Clin Infect Dis. 2020. PMID: 31782768. doi:10.1093/cid/ciz1152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。